Sharemaestro Newsreel

Revvity (RVTY) Stock Premium Faces Pressure From Thin Margins

Revvity (RVTY) stock experienced a 3% dip despite exceeding Q2 earnings expectations, raising concerns about its high P/E ratio of 52.4x and recent squeeze in net profit margin to 8.2%. The article explores both the bullish arguments, such as organic growth in diagnostics and …

Personalis (NASDAQ: PSNL) posts larger loss and strikes Tempus cash-stock merger

Personalis, a cancer genomics testing company, reported a wider loss in Q2 2026 despite increased revenue, driven by higher operating expenses. The company announced it has entered into a merger agreement to be acquired by Tempus AI, Inc. in a cash-stock deal. The merger …

Sotera Health Company (SHC) Q2 Earnings Report Preview: What To Look For

Sotera Health (NASDAQ:SHC) is set to report its Q2 earnings this Thursday before market hours. The company had a strong previous quarter, beating revenue expectations and meeting EPS estimates. Analysts anticipate a 5.2% year-on-year revenue growth for Q2, with expectations generally reconfirmed over the …

BillionToOne (NASDAQ: BLLN) posts $109.4M Q2 2026 revenue and net profit

Has Charles River Laboratories International (CRL) Outpaced Other Medical Stocks This Year?

GRAIL (Nasdaq: GRAL) Q2 revenue rises 26% as net loss narrows

Amundi Sells 32,858 Shares of Revvity Inc. $RVTY

Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution

Biodesix (NASDAQ:BDSX) Announces Earnings Results

Quest Diagnostics (DGX) Lifts 2026 Outlook As Investors Ask If The Stock Is Fully Valued

Twist Bioscience (TWST) Jumps As Revenue, Targets And Offering Reshape The Trade

Billiontoone (BLLN) Earnings Date and Reports 2026 $BLLN

Charles River Stock Hits 52-Week High - Here's Why - Charles River (NYSE:CRL)

Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates

Charles River Laboratories’s (NYSE:CRL) Q2 CY2026 Sales Top Estimates, Stock Soars

Natera (NTRA) Reports Q2: Everything You Need To Know Ahead Of Earnings

QIAGEN's growth pillars deliver 5% CER growth as U.S. testing falls

Qiagen (QGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

5 Must-Read Analyst Questions From Illumina’s Q2 Earnings Call

Waters Q2 2026 Earnings: Acquisition Doubles Revenue as GAAP Results Turn Negative

Waters Corporation reported a 113% increase in Q2 2026 revenue to $1.645 billion, primarily driven by the acquisition of Biosciences and Diagnostic Solutions businesses. Despite this revenue growth, GAAP EPS swung to a loss of $1.39 due to acquisition-related accounting adjustments. The company provided …

IDEXX Laboratories, Inc. Stock 12‑Month Price Target Raised to $719, Implies 27% Upside

Analysts have raised the average 12-month price target for IDEXX Laboratories, Inc. (IDXX) stock to $719, up from $711.64, with a range between $620 and $805. This new target suggests a potential upside of approximately 27% from its Aug. 3 closing price. The consensus …

Pacer Advisors Inc. Sells 107,271 Shares of Medpace Holdings, Inc. $MEDP

Pacer Advisors Inc. significantly reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the first quarter of 2026, selling 107,271 shares and retaining 46,381 shares valued at approximately $22.3 million. Despite this reduction, other institutional investors have increased their holdings, and the company reported …

Bank of America Corp DE Decreases Position in IQVIA Holdings Inc. $IQV

Bank of America Corp DE reduced its stake in IQVIA Holdings Inc. by 6.9% in the first quarter, selling 96,756 shares but retaining 1.30 million shares valued at over $221 million. Despite this, institutional investors collectively hold a significant 89.62% of IQVIA's stock. The …

ICON (ICLR) Earnings Reset Keeps Valuation In Focus As Investors Weigh The Rebound

Labcorp launches FDA-approved PTEN test for prostate cancer

Labcorp has launched Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay nationwide, which is the first immunohistochemistry companion diagnostic test for prostate adenocarcinoma to identify PTEN protein loss in tumors. This assay helps determine patient eligibility for treatment with AstraZeneca’s TRUQAP. The test is crucial …

WATERS CORP : BERNSTEIN RAISES TARGET PRICE TO $450 FROM $435

Bernstein has raised its target price for Waters Corp (WAT.N) to $450 from $435. This update was reported by Reuters on August 5, 2026. The article itself is a brief announcement without further details or analysis.

iMDx to Release Second Quarter Results on August 10, 2026

Insight Molecular Diagnostics Inc. (iMDx) announced it will release its second-quarter 2026 financial results after market close on August 10, 2026, followed by a live Zoom webinar for discussion. Additionally, iMDx's CEO and CFO will participate in the 11th Annual Needham Virtual MedTech & …

Waters (WAT) Stock Rises On Revenue Surge While Losses Cloud Earnings

Twist Bioscience prices $300M stock offering at $96 per share

Twist Bioscience Corporation announced it has priced an underwritten public offering of 3,125,000 shares of common stock at $96.00 per share, aiming to raise $300.0 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase additional shares. The net …

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Corporation announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at $96.00 per share, aiming to raise $300.0 million. The company plans to use the net proceeds for research and development investments, expanding manufacturing capacity …

WATERS CORP : JP MORGAN RAISES TARGET PRICE TO $400 FROM $370

JP Morgan has increased its target price for Waters Corp (WAT.N) from $370 to $400. This update reflects the analyst's revised outlook on the company's financial prospects. The article, originally published by Reuters, indicates this change occurred on August 5, 2026.

Personalis Reports Second Quarter 2026 Results and Recent Highlights

Personalis, Inc. reported strong financial results for the second quarter of 2026, with revenue growing 30% year-over-year to $22.4 million and clinical test volume surging 199%. Key achievements include securing Medicare coverage for its NeXT Personal® test for immunotherapy monitoring and neoadjuvant breast cancer …

Enterprise value to EBIT forward of bioAffinity Technologies, Inc. – NASDAQ:BIAF

This article provides financial data for bioAffinity Technologies, Inc. (NASDAQ: BIAF), specifically its Enterprise Value to EBIT forward. The content is presented through TradingView, offering an overview of financials, news, and community sentiment for the company. The data is supplied by ICE Data Services …

ICON Announces Private Offering of Notes

ICON plc announced that its subsidiary, ICON Investments Six Designated Activity Company, intends to offer senior notes in a private offering. The proceeds from this offering are planned to be used to repay outstanding borrowings under a bridge facility and a senior secured term …

GUARDANT HEALTH INC : PIPER SANDLER RAISES TARGET PRICE TO $193.00 FROM $135.00

Piper Sandler has increased its target price for Guardant Health Inc. (GH.O) shares to $193.00 from $135.00. This news was reported by Reuters on August 4, 2026. The article reiterates that the content reflects only the author's opinion and is not investment advice.